LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Blueprint Medicines Corp

Open

SectorHealthcare

127.87 0.04

Overview

Share price change

24h

Current

Min

127.51

Max

128.01

Key metrics

By Trading Economics

Income

50M

496K

Sales

3M

149M

EPS

-0.294

Profit margin

0.332

Employees

682

EBITDA

-14M

-41M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+1.35% upside

Dividends

By Dow Jones

Next Earnings

31 Jul 2025

Market Stats

By TradingEconomics

Market Cap

2.5B

8.3B

Previous open

127.83

Previous close

127.87

News Sentiment

By Acuity

34%

66%

99 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Blueprint Medicines Corp Chart

Past performance is not a reliable indicator of future results.

Related News

2 Jun 2025, 09:17 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 Jun 2025, 05:31 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

2 Jun 2025, 13:50 UTC

Earnings
Acquisitions, Mergers, Takeovers

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 Jun 2025, 10:50 UTC

Acquisitions, Mergers, Takeovers

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 Jun 2025, 10:05 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 Jun 2025, 05:06 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 Jun 2025, 05:06 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 Jun 2025, 05:05 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 Jun 2025, 05:05 UTC

Acquisitions, Mergers, Takeovers

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 Jun 2025, 05:04 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 Jun 2025, 05:04 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 Jun 2025, 05:03 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Blueprint Medicines Corporation

2 Jun 2025, 05:02 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Acquire Blueprint Medicines Corporation

Peer Comparison

Price change

Blueprint Medicines Corp Forecast

Price Target

By TipRanks

1.35% upside

12 Months Forecast

Average 129.63 USD  1.35%

High 143 USD

Low 105 USD

Based on 20 Wall Street analysts offering 12 month price targets forBlueprint Medicines Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

20 ratings

4

Buy

16

Hold

0

Sell

Technical Score

By Trading Central

87.66 / 99.25Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

99 / 380 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.